Opendata, web and dolomites

SECURE SIGNED

Secondary prEvention of CardiovascUlaR disease in the Elderly trial

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SECURE project word cloud

Explore the words cloud of the SECURE project. It provides you a very rough idea of what is the project "SECURE" about.

pharmacoeconomic    therapy    poland    stakeholders    reference    heart    benefit    strategy    infarction    older    compare    secondary    efficacy    coronary    while    subjects    risk    globally    dose    framework    polypill    requiring    intermediate    seven    fdc    france    half    disease    components    treatment    first    ge    survival    suboptimal    revascularisation    adherence    reduces    endpoints    events    myocardial    blood    patients    effect    worldwide    guidance    prevention    eligible    clinical    causes    nonfatal    ageing    tackling    strategies    65    despite    involve    czech    hospitalisation    diseases    serve    deaths    death    effectiveness    created    elderly    recommendations    cardiovascular    standard    secure    germany    fixed    differences    worsening    countries    spain    intervention    cvd    lipids    adults    separately    primary    pressure    combination    hungary    regional    medications    population    outcomes    guidelines    significantly    stroke    drafting    trial    italy    responsible    chronic    republic   

Project "SECURE" data sheet

The following table provides information about the project.

Coordinator
CENTRO NACIONAL DE INVESTIGACIONESCARDIOVASCULARES CARLOS III (F.S.P.) 

Organization address
address: CALLE MELCHOR FERNANDEZ ALMAGRO 3
city: MADRID
postcode: 28029
website: www.cnic.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.secure-h2020.eu/
 Total cost 6˙898˙301 €
 EC max contribution 5˙998˙786 € (87%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2014-two-stage
 Funding Scheme RIA
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRO NACIONAL DE INVESTIGACIONESCARDIOVASCULARES CARLOS III (F.S.P.) ES (MADRID) coordinator 1˙465˙972.00
2    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 1˙096˙546.00
3    ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI IT (MILANO) participant 1˙034˙362.00
4    SERVICIO MADRILENO DE SALUD ES (MADRID) participant 794˙166.00
5    ARTTIC FR (PARIS) participant 391˙512.00
6    FERRER INTERNATIONAL ES (BARCELONA) participant 263˙574.00
7    CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE BESANCON FR (BESANCON CEDEX) participant 232˙609.00
8    VSEOBECNA FAKULTNI NEMOCNICE V PRAZE CZ (PRAHA 2) participant 219˙883.00
9    UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU PL (WROCLAW) participant 211˙251.00
10    SEMMELWEIS EGYETEM HU (BUDAPEST) participant 184˙650.00
11    LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER UK (LONDON) participant 104˙258.00

Map

 Project objective

While Cardiovascular diseases (CVD) are the main cause of death worldwide, they are responsible for half of all deaths in Europe. The overall ageing of the European population and improving survival of patients with coronary heart disease has created a large population of older adults eligible for secondary prevention. Despite the established efficacy of cardiovascular medications, suboptimal adherence reduces their effectiveness and is the primary reason for suboptimal clinical benefit, contributing significantly to worsening of diseases and deaths at the population level. SECURE will be the first trial testing the efficacy of a fixed dose combination (FDC) polypill for secondary cardiovascular prevention in the elderly population (≥ 65 years old). The main objective is to evaluate the potential benefit of the FDC as a component of a cost-effective, globally available and comprehensive treatment strategy for secondary prevention of cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, stroke, and hospitalisation requiring revascularisation) as compared to standard therapy (the three components of the polypill given separately). As part of the secondary endpoints, SECURE will compare the effect of both strategies on adherence and intermediate measures of risk factor control such as lipids and blood pressure. Importantly, it will also measure the pharmacoeconomic impact of the FDC intervention as well as regional differences in all outcomes. The five-year project will thus involve subjects from seven different countries: Spain, Italy, France, Germany, Hungary, Poland and the Czech Republic. The findings and conclusions obtained in SECURE will allow the drafting of clinical guidelines and recommendations that will provide useful guidance and will serve as a reference framework for all stakeholders involved in tackling major challenges related to secondary prevention and treatment of chronic diseases in the elderly population.

 Deliverables

List of deliverables.
SECURE poster Websites, patent fillings, videos etc. 2020-04-01 17:10:11
Project leaflet Websites, patent fillings, videos etc. 2020-04-01 17:10:11
Detailed dissemination plan Documents, reports 2020-04-01 17:10:11
Public website Websites, patent fillings, videos etc. 2020-04-01 17:10:11

Take a look to the deliverables list in detail:  detailed list of SECURE deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Borja Ibañez, José M Castellano, Valentin Fuster
Polypill strategy at the heart of cardiovascular secondary prevention
published pages: 9-10, ISSN: 1355-6037, DOI: 10.1136/heartjnl-2018-313464
Heart 105/1 2020-04-01
2019 Jose M. Castellano, Juan Verdejo, Salvador Ocampo, Marco Martinez Rios, Enrique Gómez-Álvarez, Gabriela Borrayo, Emilio Ruiz, Borja Ibáñez, Valentin Fuster, Misael Arroyo, Maria Teresa Colosia, Juan E. Becerril, Roberto Vázquez, Elias Rodriguez, Alejandro Rodriguez, Rafael Márquez, Enrique Gomez, Juan M. González, Jose L. Ubiarco, Jose F. Barrera, Bertha Vitela, Laura A. Aranda, Víctor Pe
Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study
published pages: 31-40, ISSN: 0188-4409, DOI: 10.1016/j.arcmed.2019.04.001
Archives of Medical Research 50/1 2020-04-01
2017 Ruth Webster, Jose M Castellano, Oyere K Onuma
Putting polypills into practice: challenges and lessons learned
published pages: 1066-1074, ISSN: 0140-6736, DOI: 10.1016/s0140-6736(17)30558-5
The Lancet 389/10073 2020-04-01
2017 José M Castellano, Valentín Fuster, Catriona Jennings, Eva Prescott, Héctor Bueno
Role of the polypill for secondary prevention in ischaemic heart disease
published pages: 44-51, ISSN: 2047-4873, DOI: 10.1177/2047487317707324
European Journal of Preventive Cardiology 24/3_suppl 2020-04-01
2017 Mrs. Fiona Ecarnot, Prof. François Schiele
La polypill à travers les résultats de l\'étude HOPE 3
published pages: 12-16, ISSN: 0761-5035, DOI:
La Lettre du Cardiologue N°505 / May 2017 2020-04-01
2015 José M. Castellano, Valentín Fuster
Polypill, el policomprimido cardiovascular: del concepto a la realidad en España
published pages: 19-24, ISSN: 1131-3587, DOI: 10.1016/S1131-3587(16)30005-X
Revista Española de Cardiología Suplementos 15 2020-04-01
2015 Juan Tamargo, José M. Castellano, Valentín Fuster
The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention
published pages: S15-S23, ISSN: 0167-5273, DOI: 10.1016/S0167-5273(15)31028-7
International Journal of Cardiology 201 2020-04-01
2015 José M. Castellano, Héctor Bueno, Valentín Fuster
The cardiovascular polypill: clinical data and ongoing studies
published pages: S8-S14, ISSN: 0167-5273, DOI: 10.1016/S0167-5273(15)31027-5
International Journal of Cardiology 201 2020-04-01

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SECURE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SECURE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More